Dynavax Technologies (NASDAQ:DVAX) Downgraded to Hold Rating by StockNews.com

StockNews.com cut shares of Dynavax Technologies (NASDAQ:DVAX) from a buy rating to a hold rating in a research report released on Wednesday.

A number of other research analysts also recently issued reports on the company. The Goldman Sachs Group downgraded Dynavax Technologies from a “neutral” rating to a “sell” rating and reduced their price objective for the company from $15.00 to $12.00 in a research note on Tuesday. HC Wainwright raised their price objective on shares of Dynavax Technologies from $29.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday, January 14th.

Dynavax Technologies Price Performance

Dynavax Technologies stock opened at $12.45 on Wednesday. Dynavax Technologies has a 52 week low of $9.74 and a 52 week high of $13.89. The company’s 50 day moving average price is $12.81 and its two-hundred day moving average price is $11.92. The stock has a market cap of $1.64 billion, a P/E ratio of 95.78 and a beta of 1.32. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33.

Institutional Trading of Dynavax Technologies

Several hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC increased its holdings in Dynavax Technologies by 175.5% in the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 1,685 shares during the last quarter. US Bancorp DE boosted its position in Dynavax Technologies by 291.4% during the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,034 shares during the period. Smartleaf Asset Management LLC increased its stake in shares of Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 2,034 shares in the last quarter. Capital Performance Advisors LLP purchased a new stake in shares of Dynavax Technologies during the 3rd quarter valued at approximately $45,000. Finally, Nisa Investment Advisors LLC boosted its holdings in Dynavax Technologies by 44.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 1,679 shares during the period. 96.96% of the stock is currently owned by institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.